Abstract
The Hedyotis diffusa Willd herbal compounds (HDWHCs) are commonly used as Chinese medicine to treat cancer patients with established clinical therapeutic efficacy in China. However, the underlying mechanisms remain to be elucidated. In this study, we used freeze-dried powder of the water extracts of HDWHCs to investigate the potential mechanisms of HDWHCs in cancer treatment. HDWHCs treatment significantly inhibited vascular endothelial growth factor (VEGF) mRNA levels and VEGF transcriptional activation in cancer cells. HDWHCs also had a remarkable inhibitory effect on the expression of hypoxia-inducible factor 1alpha (HIF-1alpha). Forced expression of HIF-1α restored VEGF transcriptional activation inhibited by HDWHCs, indicating that HDWHCs suppressed VEGF expression through decreasing HIF-1alpha expression. Moreover, HDWHCs inhibited cyclooxygenase-2 (COX-2) expression, and overexpression of HIF-1alpha restored HDWHCs’ inhibitory effect on COX-2 at transcriptional level. These findings may provide better understanding of HDWHCs’ anti-cancer mechanism in cancer treatment.
Similar content being viewed by others
References
Anan K, Morisaki T, Katano M, Ikubo A, Kitsuki H, Uchiyama A, Kuroki S, Tanaka M, Torisu M (1996). Vascular endothelial growth factor and platelet-derived growth factor are potential angiogenic and metastatic factors in human breast cancer. Surgery, 119(3): 333–339
Cao Z, Liu L Z, Dixon D A, Zheng J Z, Chandran B, Jiang B H (2007). Insulin-like growth factor-I induces cyclooxygenase-2 expression via PI3K, MAPK and PKC signaling pathways in human ovarian cancer cells. Cell Signal, 19: 1542–1553
Carmeliet P, Dor Y, Herbert J M, Fukumura D, Brusselmans K, Dewerchin M, Neeman M, Bono F, Abramovitch R, Maxwell, P, Koch C J, Ratcliffe P, Moons L, Jain R K, Collen D, Keshert E (1998). Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature, 394(6692): 485–490
Carmeliet P, Jain R K (2000). Angiogenesis in cancer and other diseases. Nature, 407: 249–257
Cebe-Suarez S, Zehnder-Fjallman A, Ballmer-Hofer K (2006). The role of VEGF receptors in angiogenesis; complex partnerships. Cell Mol Life Sci, 63: 601–615
Cheng A S, Chan H L, To K F, Leung WK, Chan K K, Liew C T, Sung J J (2004). Cyclooxygenase-2 pathway correlates with vascular endothelial growth factor expression and tumor angiogenesis in hepatitis B virus-associated hepatocellular carcinoma. Int J Oncol, 24(4): 853–860
Ellis L M, Hicklin D J (2008). VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer, 8(8): 579–591
Fang J, Zhou Q, Liu L Z, Xia C, Hu X, Shi X, Jiang B H (2007). Apigenin inhibits tumor angiogenesis through decreasing HIF-1alpha and VEGF expression. Carcinogenesis, 28(4): 858–864
Folkman J (1995). Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med, 333(26): 1757–1763
Forsythe J A, Jiang B H, Iyer N V, Agani F, Leung S W, Koos R D, Semenza G L (1996). Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol, 16(9): 4604–4613
Fu B, Xue J, Li Z, Shi X, Jiang B H, Fang J (2007). Chrysin inhibits expression of hypoxia-inducible factor-1alpha through reducing hypoxia-inducible factor-1alpha stability and inhibiting its protein synthesis. Mol Cancer Ther, 6(1): 220–226
Jiang B H, Semenza G L, Bauer C, Marti H H (1996). Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. Am J Physiol, 271(4 Pt 1): C1172–C1180
Kaidi A, Qualtrough D, Williams A C, Paraskeva C (2006). Direct transcriptional up-regulation of cyclooxygenase-2 by hypoxiainducible factor (HIF)-1 promotes colorectal tumor cell survival and enhances HIF-1 transcriptional activity during hypoxia. Cancer Res, 66(13): 6683–6691
Kim Y, Park E J, Kim J, Kim Y, Kim S R, Kim Y Y (2001). Neuroprotective constituents from Hedyotis diffusa. J Nat Prod, 64(1): 75–78
Levy A P, Levy N S, Iliopoulos O, Jiang C, Kaplin W G Jr, Goldberg M A (1997). Regulation of vascular endothelial growth factor by hypoxia and its modulation by the von Hippel-Lindau tumor suppressor gene. Kidney Int, 51(2): 575–578
Li C, Xue X, Zhou D, Zhang F, Xu Q, Ren L, Liang X (2008). Analysis of iridoid glucosides in Hedyotis diffusa by high-performance liquid chromatography/electrospray ionization tandem mass spectrometry. J Pharm Biomed Anal, 48(1): 205–211
Liao L L, Chen C H, Chen G C (1979). Formosan medicinal herb, Hedyotis diffusaWilld, as an antitumor agent. Taiwan Yi Xue Hui Za Zhi, 78(7): 658–660
Liu L Z, Fang J, Zhou Q, Hu X, Shi X, Jiang B H (2005). Apigenin inhibits expression of vascular endothelial growth factor and angiogenesis in human lung cancer cells: implication of chemoprevention of lung cancer. Mol Pharmacol, 68(3): 635–643
Liu X H, Kirschenbaum A, Yao S, Stearns M E, Holland J F, Claffey K, Levine A C (1999). Upregulation of vascular endothelial growth Min WANG et al. HDWHCs inhibit VEGF 367 factor by cobalt chloride-simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line. Clin Exp Metastasis, 17(8): 687–694
Lu C M, Yang J J, Wang P Y, Lin C C (2000). A new acylated flavonol glycoside and antioxidant effects of Hedyotis diffusa. Planta Med, 66(4): 374–377
Majima M, Hayashi I, Muramatsu M, Katada J, Yamashina S, Katori M (2000). Cyclo-oxygenase-2 enhances basic fibroblast growth factor-induced angiogenesis through induction of vascular endothelial growth factor in rat sponge implants. Br J Pharmacol, 130(3): 641–649
Majima M, Isono M, Ikeda Y, Hayashi I, Hatanaka K, Harada Y, Katsumata O, Yamashina S, Katori M, Yamamoto S (1997). Significant roles of inducible cyclooxygenase (COX)-2 in angiogenesis in rat sponge implants. Jpn J Pharmacol, 75(2): 105–114
Matsubayashi H, Infante J R, Winter J, Klein A P, Schulick R, Hruban R, Visvanathan K, Goggins M (2007). Tumor COX-2 expression and prognosis of patients with resectable pancreatic cancer. Cancer Biol Ther, 6(10): 1569–1575
Maxwell P H, Dachs G U, Gleadle J M, Nicholls L G, Harris A L, Stratford I J, Hankinson O, Pugh CW, Ratcliffe P J (1997). Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci U S A, 94(15): 8104–8109
Maxwell P H, Wiesener M S, Chang G W, Clifford S C, Vaux E C, Cockman M E, Wykoff C C, Pugh C W, Maher E R, Ratcliffe P J (1999). The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature, 399(6733): 271–275
Mazure N M, Chen E Y, Yeh P, Laderoute K R, Giaccia A J (1996). Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression. Cancer Res, 56(15): 3436–3440
Murono S, Inoue H, Tanabe T, Joab I, Yoshizaki T, Furukawa M, Pagano J S (2001). Induction of cyclooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells. Proc Natl Acad Sci U S A, 98(12): 6905–6910
Noriyuki M, Sumi T, Zhi X, Misugi F, Nobeyama H, Yoshida H, Matsumoto Y, Yasui T, Honda K, Ishiko O (2007). Vascular endothelial growth factor, matrix metalloproteinases, and cyclooxygenase-2 influence prognosis of uterine cervical cancer in young women. Int J Oncol, 31(3): 531–536
Olsson A K, Dimberg A, Kreuger J, Claesson-Welsh L (2006). VEGF receptor signalling-in control of vascular function. Nat Rev Mol Cell Biol, 7(5): 359–371
Plate K H, Breier G, Weich H A, Risau W (1992). Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature, 359(6398): 845–848
Richard D E, Berra E, Pouyssegur J (2000). Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1alpha in vascular smooth muscle cells. J Biol Chem, 275(35): 26765–26771
Salceda S, Caro J (1997). Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem, 272(36): 22642–22647
Sawaoka H, Tsuji S, Tsujii M, Gunawan E S, Sasaki Y, Kawano S, Hori M (1999). Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. Lab Invest, 79(12): 1469–1477
Shi Y, Wang C H, Gong X G (2008). Apoptosis-inducing effects of two anthraquinones from Hedyotis diffusa WILLD. Biol Pharm Bull, 31(6): 1075–1078
Shibuya M (2008). Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis. BMB Rep, 41: 278–286
Spencer J P, Vauzour D, Rendeiro C (2009). Flavonoids and cognition: the molecular mechanisms underlying their behavioural effects. Arch Biochem Biophys, 492(1–2): 1–9
Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois R N (1998). Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell, 93(5): 705–716
von Rahden B H, Stein H J, Pühringer F, Koch I, Langer R, Piontek G, Siewert J R, Höfler H, Sarbia M (2005). Coexpression of cyclooxygenases (COX-1, COX-2) and vascular endothelial growth factors (VEGF-A, VEGF-C) in esophageal adenocarcinoma. Cancer Res, 65(12): 5038–5044
Zhong H, De Marzo A M, Laughner E, Lim M, Hilton D A, Zagzag D, Buechler P, Isaacs W B, Semenza G L, Simons J W (1999). Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res, 59(22): 5830–5835
Author information
Authors and Affiliations
Corresponding author
Additional information
Both authors contributed equally to this work
Rights and permissions
About this article
Cite this article
Wang, M., Shi, Z., Liu, D. et al. Inhibition of vascular endothelial growth factor expression by Chinese medicine of Hedyotis diffusa Willd herbal compounds. Front. Biol. 5, 361–368 (2010). https://doi.org/10.1007/s11515-010-0033-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11515-010-0033-6